NEW YORK, NY / ACCESSWIRE / May 21, 2021 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.
Repro Med Systems, Inc. (NASDAQ:KRMD)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/repro-med-systems-inc-loss-submission-form?prid=16039&wire=1
Lead Plaintiff Deadline: May 25, 2021
Class Period: August 4, 2020 - January 25, 2021
Allegations against KRMD include that: (1) starting in January 2020, Repro Med Systems ramped up the use of allowances, including growth rebates, to retain key customers and to incentivize growth; (2) as the rebates accrued, the Company's net sales were reasonably likely to decline; and (3) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
3D Systems Corporation (NYSE:DDD)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/3d-systems-corp-loss-submission-form?prid=16039&wire=1
Lead Plaintiff Deadline: June 8, 2021
Class Period: May 6, 2020 - March 1, 2021
Allegations against DDD include that: (1) 3D Systems lacked proper internal controls over financial reporting; and (2) as a result, 3D Systems' public statements were materially false and/or misleading at all relevant times.
ChemoCentryx, Inc. (NASDAQ:CCXI)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/chemocentryx-inc-loss-submission-form?prid=16039&wire=1
Lead Plaintiff Deadline: July 6, 2021
Class Period: November 26, 2019 - May 3, 2021
Allegations against CCXI include that: (1) the study design of the Phase III ADVOCATE trial presented issues about the interpretability of the trial data to define a clinically meaningful benefit of avacopan and its role in the management of ANCA-associated vasculitis; (2) the data from the Phase III ADVOCATE trial raised serious safety concerns for avacopan; (3) these issues presented a substantial concern regarding the viability of ChemoCentryx's New Drug Application ("NDA") for avacopan for the treatment of ANCA-associated vasculitis; and (4) as a result of the foregoing, Defendants' public statements were materially false and misleading at all relevant times.
To learn more contact Vincent Wong, Esq. either via email [email protected] or by telephone at 212.425.1140.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: [email protected]
SOURCE: The Law Offices of Vincent Wong